trending Market Intelligence /marketintelligence/en/news-insights/trending/5Yw3rGmovh-3UIJsF2gvCA2 content esgSubNav
In This List

US FDA approves Dimension Therapeutics' application for urea cycle disorder drug

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


US FDA approves Dimension Therapeutics' application for urea cycle disorder drug

The U.S. FDA accepted Dimension Therapeutics Inc.'s investigational new drug application for DTX301 to treat ornithine transcarbamylase deficiency, a genetic disorder that causes ammonia to accumulate in the blood.

Dimension expects to start a phase 1/2 clinical trial to evaluate the urea cycle disorder drug in patients with the deficiency by the end of 2016.